Sanofi, Regeneron rack up some cost-savings data for their PCSK9 contender Praluent

It's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a severe form of high cholesterol cut back on pricey and cumbersome aphaeresis treatments, new late-stage study data show. More from FiercePharmaMarketing

Suggested Articles

California CDMO JSR Life Sciences is building a new home for two subsidiaries as it hopes to enter the competitive biologics market.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Three facts about how distributors are managing in-demand inventory.